A case of EBV driven haemophagocytic lymphohistiocytosis complicating a teenage Crohn's disease patient on azathioprine, successfully treated with rituximab

Journal of Crohn's and Colitis

Volumn 7, Issue 4, 2013, Pages 314-317

  Fitzgerald, Michael P ^a   Armstrong, Lawrence ^b   Hague, Rosie ^a   Russell, Richard K ^a  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b CROSSHOUSE HOSPITAL   (United Kingdom)

Author keywords

Azathioprine; Crohn's disease; Epstein Barr virus; Haemophagocytic lymphohistiocytosis; Rituximab

Indexed keywords

AZATHIOPRINE; METHOTREXATE; OSELTAMIVIR; PREDNISOLONE; RITUXIMAB;

ABDOMINAL PAIN; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CERVICAL LYMPHADENOPATHY; CHILD; CROHN DISEASE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; ERYTHEMA; FEVER; GLOSSITIS; HEADACHE; HEMOPHAGOCYTIC SYNDROME; HEPATOSPLENOMEGALY; HUMAN; INFLUENZA A (H1N1); MYALGIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; REMISSION; SCHOOL CHILD; TONSILLITIS; TREATMENT DURATION; ULTRASOUND; VIRUS LOAD; VOMITING;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AZATHIOPRINE; CROHN DISEASE; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC;

EID: 84875255740     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.05.002     Document Type: Article

References (35)

1. Egeler R.M., Shapiro R., Loechelt B., Filipovich A. Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 1996, 18(4):340-345.
2. Ohga S., Matsuzaki A., Nishizaki M., Nagashima T., Kai T., Suda M., et al. Inflammatory cytokines in virus-associated hemophagocytic syndrome. Interferon-gamma as a sensitive indicator of disease activity. Am J Pediatr Hematol 1993, 15(3):291-298.
3. Watanabe M., Shimamoto Y., Yamaguchi M., Inada S., Miyazaki S., Sato H. Viral-associated haemophagocytosis and elevated serum TNF-alpha with parvovirus-B19-related pancytopenia in patients with hereditary spherocytosis. Clin Lab Haematol 1994, 16(2):179-182.
4. Henter J.I., Elinder G., Sder O., Hansson M., Andersson B., Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991, 78(11):2918-2922.
5. Janka G.E. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr 1983, 140(3):221-230.
6. Henter J., Horne A., Aric M., Egeler R.M., Filipovich A., Imashuku S., et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007, 48(2):124-131.
7. Arico M., Imashuku S., Clementi R., Hibi S., Teramura T., Danesino C., et al. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood 2001, 97(4):1131-1133.
8. Meeths Clinical presentation of Griscelli syndrome type 2 and spectrum of RAB27A mutations. Pediatr Blood Cancer 2010, 54(4):563-572.
9. Jayaranee S., Menaka N. Chediak-Higashi syndrome: a case report. Malays J Pathol 2004, 26(1):53-57.
10. Gencik A., Signer E., Mller H. Genetic analysis of familial erythrophagocytic lymphohistiocytosis. Eur J Pediatr 1984, 142(4):248-252.
11. Henter J., Samuelsson-Horne A., Aric M., Egeler R.M., Elinder G., Filipovich A., et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002, 100(7):2367-2373.
12. Chang C.S., Wang C.H., Su I.J., Chen Y.C., Shen M.C. Hematophagic histiocytosis: a clinicopathologic analysis of 23 cases with special reference to the association with peripheral T-cell lymphoma. J Formos Med Assoc 1994, 93(5):421-428.
13. N'guyen Y., Andreoletti L., Patey M., Lecoq-Lafon C., Cornillet P., Lon A., et al. Fatal Epstein-Barr virus primo infection in a 25-year-old man treated with azathioprine for Crohn's disease. J Clin Microbiol 2009, 47(4):1252-1254.
14. Rouphael N., Talati N., Vaughan C., Cunningham K., Moreira R., Gould C. Infections associated with haemophagocytic syndrome. Lancet Infect Dis 2007, 7(12):814-822.
15. Serrano A.G., Martn F.P., Guerrero Igea F.J., Muoz J.G., Gil S.P. Fatal infectious mononucleosis during azathioprine treatment in Crohn's disease. Gastroenterol Hepatol 2000, 23(1):7-8.
16. Francolla K., Altman A., Sylvester F. Hemophagocytic syndrome in an adolescent with Crohn disease receiving azathioprine and infliximab. J Pediatr Gastroenterol Nutr 2008, 47(2):193-195.
17. Deneau M., Wallentine J., Guthery S., O'Gorman M., Bohnsack J., Fluchel M., et al. Natural killer cell lymphoma in a pediatric patient with inflammatory bowel disease. Pediatrics October 1 2010, 126(4):e977-e981.
18. Biank V.F., Sheth M.K., Talano J., Margolis D., Simpson P., Kugathasan S., et al. Association of Crohn's disease, thiopurines, and primary Epstein-Barr virus infection with hemophagocytic lymphohistiocytosis. J Pediatr 2011, 159(5):808-812. [11].
19. Jaspers G., Verkade H., Escher J., de Ridder L., Taminiau J.A.J.M., Rings E.H.H.M. Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm Bowel Dis 2006, 12(9):831-836.
20. Markowitz J., Grancher K., Kohn N., Lesser M., Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000, 119(4):895-902. [10].
21. Posthuma E.F., Westendorp R.G., van der Sluys Veer A., Kluin-Nelemans J.C., Kluin P.M., Lamers C.B. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn's disease with azathioprine. Gut 1995, 36(2):311-313.
22. Beaugerie L., Brousse N., Bouvier A.M., Colombel J.F., Lémann M., Cosnes J., et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374(9701):1617-1625. [11/7-13].
23. Ross Epstein-Barr virus-associated lymphoproliferative disorder in Crohn disease treated with azathioprine. J Pediatr Gastroenterol Nutr 2010, 51(2):229-231.
24. Larvol L., Soule J.C., Le Tourneau A. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease. N Engl J Med 1994, 331(13):883-884.
25. Ishii E., Ohga S., Imashuku S., Yasukawa M., Tsuda H., Miura I., et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 2007, 86(1):58-65.
26. Maloney D.G., Liles T.M., Czerwinski D.K., Waldichuk C., Rosenberg J., Grillo-Lopez A., et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994, 84(8):2457-2466.
27. Serrate C., Silva-Moreno M., Dartigues P., Poujol-Robert A., Sokol H., Gorin N.C., et al. Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease. Inflamm Bowel Dis 2009, 15(10):1449-1451.
28. Dayharsh G.A., Loftus J., Edward V., Sandborn W.J., Tremaine W.J., Zinsmeister A.R., et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002, 122(1):72-77. [1].
29. Milone M., Tsai D., Hodinka R., Silverman L., Malbran A., Wasik M., et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 2005, 105(3):994-996.
30. Milpied N., Vasseur B., Parquet N., Garnier J.L., Antoine C., Quartier P., et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000, 11(Suppl. 1):113-116. [1].
31. zur Stadt U., Beutel K., Weber B., Kabisch H., Schneppenheim R., Janka G., et al. A91V is a polymorphism in the perforin gene not causative of an FHLH phenotype. Blood September 15 2004, 104(6):1909-1910.
32. Lee S.M., Villanueva J., Sumegi J., Zhang K., Kogawa K., Davis J., et al. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J Med Genet 2004, 41(2):137-144.
33. Voskoboinik I., Trapani J. Addressing the mysteries of perforin function. Immunol Cell Biol 2006, 84(1):66-71.
34. Rahier J.F., Ben-Horin S., Chowers Y., Conlon C., De Munter P., D'Haens G., et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infection in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91.
35. Savoie A., Perpte C., Carpentier L., Joncas J., Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994, 83(9):2715-2722.